Catharina Bäärnhielm - Chairman of the Board
Born 1952. Chairman of Cereno Scientific since November 2015. Bäärnhielms has a long experience from a variety of senior roles in the pharmaceutical industry, most recently as VP and Global Project Manager at AstraZeneca. Bäärnhielm’s experience covers all phases of the drug development process, from idea to finished drug. Bäärnhielm has extensive experience of global research and development strategies for both small molecules and biologics in various disease areas. Bäärhielm has headed up a large research organization and has extensive experience of running collaborations between industry and academia. Bäärnhielm is Chairman of the Board of Cereno Scientific AB and a member of the GU Ventures board of directors. Bäärnhielm is a pharmacist and holds a PhD in pharmacokinetics and drug metabolism.
Björn Dahlöf - Board Member
Born 1953. Board member since the company was started in April 2012 and Cheif Medical Officer since september 2018. Dahlöf has practiced General Internal Medicine at Sahlgrenska Hospital for over 35 years and is Associate Professor of Cardiovascular Prevention at the Sahlgrenska Academy, University of Gothenburg. Dahlöf has extensive experience in cardiovascular research, pharmacology, drug development and clinical trials (all phases) and has lectured in these areas internationally. Dahlöf has for many years been an adviser to small and large pharmaceutical companies regarding drug development in all phases from preclinical development to larger lifecycle management studies after registration. Dahlöf has initiated and led several major national and multinational mortality and morbidity studies that have had significance for guidelines in cardiovascular prevention. In total, Dahlöf has published around 400 articles on scientific works in prestigious scientific journals. Dahlöf also has considerable experience from startups and running small companies within drug development and clinical trials.
Jonas Faijerson Säljö - Board Member
Born 1977. Board member since the company was started in April 2012. Faijerson Säljö is a PhD in Neurobiology and a licensed pharmacist. He has a research background in the stroke area with wide-ranging experience in the commercialization of medical innovations. Faijerson Säljö has significant expertise in intellectual property and business development experience from a large number of companies in the life science area. He is currently employed as Senior IP Business Consultant and Office Manager at Synergon AB.
Sverker Jern - Board Member
Born 1954. Board member of Cereno Scientific AB since April 12, 2012. Jern is Professor of Cardiovascular Physiology at Gothenburg University and chief of Clinical Physiology at the Sahlgrenska University Hospital. It is Jern’s research at the Wallenberg Laboratory for Cardiovascular and Metabolic Research at the Sahlgrenska Academy, Gothenburg, which discovered the molecular mechanisms that control the body's inherent protection against blood clots. These basic research findings are the basis for the new treatment that Cereno Scientific is developing. Jern has published about 150 scientific papers in respected scientific journals and has also developed and published medical textbooks and interactive training programs. Jern has been in charge of ECG analysis in several of the largest international cardiovascular intervention studies. Jern is one of the founders of Cereno Scientific AB.
Anders Svensson - Board Member
Born 1951. Board member since October 2018. Licensed physician, medical doctor and lecturer with over 20 years of experience in academic medicine; his scientific focus is cardiovascular diseases. After a period in academia, Dr. Svensson moved to AstraZeneca, where as a Vice President he was responsible for clinical development of cardiovascular — and later gastrointestinal — drugs. In 2007, he moved to Switzerland to lead global clinical development of diabetes and cardiovascular drugs at one of the world’s leading drug companies, F. Hoffmann-LaRoche. After nearly 20 years in leading positions in the global drug industry, with management responsibilities for groups in Europe, the US and China, Anders Svensson has a great deal of experience in international drug development and an extensive contact network. He has nearly 100 publications to his name, and is currently a consultant and board member at Tikomed AB.
Klementina Österberg - Board Member
Born 1975. CEO of GU Ventures, University of Gothenburg’s holding company. GU Ventures operates as an incubator and invests in the commercialization of innovations. Österberg is a graduate in business administration and works actively with financing, start-ups and managing companies within the GU Ventures AB sphere. Previous assignments include the business plan competition, Venture Cup, various Volvo companies, Daimler Chrysler and Geveko Industries.
Niklas Bergh - Deputy Member
Born 1979. Bergh has been a deputy director at Cereno Scientific AB since November 2015. He is responsible for the R&D program and is Cereno Scientific's Chief Scientific Officer (CSO). Bergh is Associate Professor in Experimental Cardiology at Sahlgrenska Academy, University of Gothenburg. Bergh is a specialist in internal medicine and a resident physician in cardiology. Bergh works as a cardiology specialist at Sahlgrenska University Hospital and is an expert on the body's defense system against blood clots. Bergh has extensive experience from experimental and clinical research with primary focus on understanding and stimulating the body's own defense system against blood clots. Bergh is one of the founders of Cereno Scientific AB.
Jan Pilebjer - Deputy Member
Jan Pilebjer, born 1954, holds an economics degree from Uppsala University, is Business Adviser and Business Intelligence Officer at GU Ventures AB. Pilebjer has worked in major worldwide companies and has founded and operated smaller start-up companies in both diagnostics and pharmaceuticals. Among Pilebjer’s international and industrial experiences are companies such as Baxter Healthcare Inc., Nycomed AS, KabiVitrum AB, Medirox AB, Biopool AB and Upjohn AB, where he had his base in countries such as Switzerland, the United States and Denmark.